Best Sellers
Retatrutide (Pen)
Price range: £49.99 through £113.99Retatrutide
Metabolics & GLP-1 — Triple Agonist
GIP/GLP-1/GCG triple agonist peptide
Retatrutide is an investigational once-weekly triple agonist of the GIP, GLP-1, and glucagon receptors (triple G). In the Phase II SURMOUNT dose-finding trial, 12 mg weekly produced mean body weight loss of 24.2% at 48 weeks — the highest reported for any pharmacological agent in a controlled trial.
Mechanism:
GIP + GLP-1 + glucagon triple agonist
Stage:
Phase III trials (as of 2026)
Peak Phase II Weight Loss:
24.2% at 48 weeks
Retatrutide (Vial)
Price range: £58.99 through £92.99Retatrutide
Metabolics & GLP-1 — Triple Agonist
GIP/GLP-1/GCG triple agonist peptide
Retatrutide is an investigational once-weekly triple agonist of the GIP, GLP-1, and glucagon receptors (triple G). In the Phase II SURMOUNT dose-finding trial, 12 mg weekly produced mean body weight loss of 24.2% at 48 weeks — the highest reported for any pharmacological agent in a controlled trial.
Mechanism:
GIP + GLP-1 + glucagon triple agonist
Stage:
Phase III trials (as of 2026)
Peak Phase II Weight Loss:
24.2% at 48 weeks
Tirzepatide (Pen)
Price range: £54.99 through £74.99Tirzepatide
Metabolics & GLP-1 — GIP + GLP-1 Dual Agonist
Tirzepatide is a first-in-class dual GIP and GLP-1 receptor agonist approved for type 2 diabetes and obesity. Clinical trials demonstrate superior weight loss compared to semaglutide, with up to 22.5% mean body weight reduction at 15 mg weekly dosing.
Tirzepatide (Vial)
Price range: £34.99 through £54.99Tirzepatide
Metabolics & GLP-1 — GIP + GLP-1 Dual Agonist
Tirzepatide is a first-in-class dual GIP and GLP-1 receptor agonist approved for type 2 diabetes and obesity. Clinical trials demonstrate superior weight loss compared to semaglutide, with up to 22.5% mean body weight reduction at 15 mg weekly dosing.
